The PBM Contract: Rebates, Pricing Commitments, Fees and Audit Rights

PBM contract rebate definitions and audit rights determine which manufacturer payments reach the plan and whether the plan can trace them. A pricing commitment adds another question: which prescriptions count when the PBM measures its performance? If you work in contracting, rebate accounting or plan finance, you may see the promise in one document and the money in another. The definition, the payment and the final reconciliation have to tell the same story.

The Agreements Behind the Pharmacy Benefit

The sponsor agreement sets what the health care plan pays the PBM. The pharmacy network agreement sets what the PBM pays the pharmacy. The manufacturer agreement sets rebate or service payments coming from the drugmaker. Each controls a different part of the transaction.

Spread pricing sits between the sponsor charge and pharmacy reimbursement. A later contractual shortfall payment can change that difference. An affiliated pharmacy also has its own purchasing costs and dispensing revenue, while a rebate aggregator may receive manufacturer money before the PBM receives its share.

That is why the signed agreement, pricing schedules, amendments and reconciliation terms belong together. A headline discount says little about the final cost until the defined claims and later adjustments are attached to it. The same applies to a promise to pass through rebates: the manufacturer agreement and the sponsor agreement may define different amounts.

The patient’s bill adds another distinction. A rebate paid later to the sponsor reduces the sponsor’s net cost. When coinsurance uses the higher price at the pharmacy counter, that later payment does not itself reduce the patient’s bill. A bigger rebate and a cheaper prescription are different promises.

What Does 100 Percent Pass-Through Cover?

A full pass-through promise covers only the money the contract defines as a rebate, on the claims it covers, paid to the companies it names. Exclusions for purchasing discounts, manufacturer services or particular pharmacy channels can leave money outside that promise.

The word all does a lot of selling. The defined noun after it does the accounting.

Sandia’s procurement scope for PBM services beginning in 2013 shows how specifically a buyer can describe that noun. Its requested rebate definition included base, formulary, incentive and market-share rebates, plus attributable administrative and data fees received from manufacturers or through an intermediary. It sought pass-through and audit access for those receipts. Educational grants had separate treatment, tied to educational expenses and represented as unrelated to members’ prescription services.

The manufacturer side matters just as much. A service payment has an underlying agreement, an identified service and a recipient. The sponsor’s rebate report may carry only the amount assigned to the rebate category. For an accountant who knows where the manufacturer payment first landed, that classification can explain what the sponsor never sees.

How Pricing Commitments Are Measured

A PBM pricing commitment depends on the drug classification, pharmacy channel, benchmark, eligible claims and measurement period. The reconciliation then determines whether the PBM owes a shortfall payment and whether another category’s surplus can erase it.

Average wholesale price is a pricing benchmark. It is different from the pharmacy’s acquisition invoice. A discount against that benchmark, a maximum allowable cost list and a manufacturer rebate each describe a different part of the price.

Under Sandia’s requested traditional pricing arrangement, the brand discount commitment excluded retail usual-and-customary claims, while the generic discount commitment included those claims and both MAC and non-MAC pricing. That arrangement’s per-claim rebate commitment included brand and generic prescriptions at retail and mail order. Changing which claims entered the calculation could change the result before anyone changed a rate.

Drug classification mattered too. The scope required a drug designated as generic to remain generic for the contract term unless the original designation was an error. It also tied the AWP benchmark to the product dispensed and its dispensing date. Those terms give a claims analyst something concrete to compare with the calculation.

True-Ups and Offsets Change the Final Payment

A true-up compares actual performance with the contractual promise and settles the difference. Whether one category can cover another category’s shortfall comes from the offset language.

Sandia sought dollar-for-dollar reimbursement of shortfalls against pricing commitments and barred offsets between components or channels, with a stated exception for retail and mail-order rebates. Its proposed schedule called for quarterly rebate payments and a full annual reconciliation. The interim payment and the final calculation ran on separate clocks.

What a PBM Audit Right Reaches

Audit access must reach the records behind the promise: pharmacy reimbursement, manufacturer receipts, affiliate allocations and the calculations used to settle contractual shortfalls. A contract review identifies those obligations. Testing claims and payments shows whether the PBM performed them.

Sandia’s requested rights reached paid claims, the processing system, performance commitments, MAC rates and the formulary rebate program. They included how utilization was reported to manufacturers, how rebates were earned and how payments were allocated to Sandia. Its specialty-program audit also reached documented patient and provider interventions. Sandia also sought an independent auditor, access during the contract term on written notice, and no restriction on the period of paid claims reviewed.

Sandia’s proposed market-check process called for a contractor response and pricing discussions when its savings threshold was met, with an exit if the parties could not agree. The dispute terms gave the buyer somewhere to go with the finding.

Can an Affiliate Keep Fees?

An affiliate can keep payments outside the contract’s pass-through promise. But in Compass Rose, the inspector general found that retained rebates belonged to the plan.

The Office of Personnel Management’s inspector general examined precisely that gap in its Compass Rose pharmacy audit, issued in November 2024. The audit covered Express Scripts’ administration of the plan’s Federal Employees Health Benefits pharmacy operations for contract years 2017 through 2022.

For the rebate finding, auditors compared manufacturer agreements with amounts passed to the plan. They found that Ascent Health Services retained rebates under lower percentages agreed internally with Express Scripts. Ascent received the manufacturer money first. Comparing only what Express Scripts received with what it sent the plan would miss what Ascent kept.

After allowing for payments already made to meet contractual rebate commitments, the auditors identified $9,524,945 in rebate principal due for June 2019 through December 2021. Compass Rose reported that Express Scripts transferred that principal back in March 2024.

The audit also examined discounts on drugs dispensed through the PBM’s own mail and specialty pharmacies. The auditors treated those purchasing discounts as part of the plan’s acquisition-cost calculation. The inventory price needed its supporting credits, just as the rebate report needed its upstream receipts.

The responses matter. Compass Rose disputed the separate retail-pricing finding, saying the PBM had passed through what it paid pharmacies and reconciled the negotiated pricing commitments. The inspector general maintained that the pharmacy agreements contained greater discounts that the plan should have received. The disagreement was over which contractual price the plan was entitled to, not whether the spreadsheet added up.

The Rebate Report Against the Contract

A rebate report needs the claims period that earned the money, the eligible population, the payment category and the later true-up. A check received this quarter can belong to an earlier period. The receipt date alone cannot settle whether the promise was met.

The useful comparison runs from the original claim and any reversal to the pharmacy remittance and sponsor charge, then to the manufacturer or aggregator invoice, receipt and allocation. The final reconciliation shows which contractual shortfall payments, credits and offsets changed the result. We connect those records with the people who understand how the business produced them.

Claims administration can change the underlying population. In its 2013 guidance on post-point-of-sale adjustments, the Centers for Medicare & Medicaid Services addressed drugs billed but never dispensed: the cost was to be recouped and the Prescription Drug Event deleted, with no direct and indirect remuneration reported for that event. A paid claim, an actual dispense and a later correction describe different stages of the same prescription.

A Contractual Rebate and a Medicare Report Answer Different Questions

For Medicare Part D, the sponsor’s reporting obligation can reach money an intermediary retains. The agency’s reporting guidance for contract year 2023 expressly includes qualifying price concessions whether the intermediary keeps them or passes them to the sponsor.

The guidance also separates bona fide service fees from rebate reporting. It requires actual, itemized services for the manufacturer and support for fair market value, among its conditions. When an otherwise qualifying fee exceeds fair market value, the excess belongs in DIR. The account label therefore needs the service and valuation records behind it. For an insider, the connection is specific: what did the manufacturer pay, what did the PBM retain, how did the sponsor classify it, and what reached the Medicare reconciliation?

When the Contract Becomes a Whistleblower Question

A healthcare fraud whistleblower case connects the contractual promise to a false claim or report affecting government payment, and to what the company knew or deliberately ignored. The contract, the accounting treatment and the instructions inside the business can each supply part of that connection.

Elixir’s Alleged Service Fees Changed the Medicare Report

In the Elixir settlement agreement, the United States alleged that retained manufacturer rebates were falsely reported as bona fide service fees in Elixir Insurance Company’s Medicare Part D reports. The agreement, reached in 2024, covered allegations from 2014 through 2020 and described retention without the manufacturers’ knowledge. A whistleblower started the case, and the government joined it.

The whistleblower’s complaint called the PBM EPS and put its supposed services directly at issue:

The agreement described a formula of 20% of estimated manufacturer rebates during 2014 through 2019, changing to 5.5% of wholesale acquisition cost of rebateable drugs in 2020. Elixir Insurance Company and Rite Aid agreed to $101 million in fixed settlement payments. The government’s allegation was that the false reports deprived Medicare, and the taxpayers funding it, of manufacturer discounts. We see the absurdity in the allegation: a fee for services the manufacturer did not even know it was paying for.

Caremark’s Offsets Reached Across Commercial and Medicare Claims

A whistleblower brought the Caremark case, and the government did not join it. Caremark’s pricing for Walgreens and Rite Aid prescriptions in 2013 and 2014 supplied a different connection. In its June 2025 trial findings, the federal court found that higher Part D payments relative to an overall generic effective-rate commitment reduced Caremark’s commercial reconciliation obligation. The resulting price concessions belonged in Medicare reporting even when no separate refund check changed hands.

The court also examined an audit that found matching payments at the pharmacy counter. That audit’s scope excluded DIR reporting and did not tell the sponsor about the offsets. We see the problem plainly: a correct comparison at the counter can leave the adjustment that mattered outside the audit.

For the contracting employee, the offset clause is visible. For the finance employee, it is the reconciliation workbook. For the reporting employee, it is the amount sent to the sponsor. Bringing those views together can show how government payments were affected. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What the Report Leaves Out

If you work with PBM contracts, manufacturer payments or plan reconciliations, talk with our whistleblower experts about the promise and the payment you see. We build your strongest PBM whistleblower case with you across the agreements, accounting and government reports, and bring in PBM fraud whistleblower lawyers who understand rebate and pricing disputes. You know where the explanation breaks down; we stay beside you as we pursue it.